Press Releases

Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth

Annual General Meeting of Kuros Biosciences approves all resolutions

Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026

Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025

Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences

Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion

Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference

Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025

Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025

Kuros statement on media inquiry concerning former Board member

Kuros Biosciences announces changes in the Board of Directors

Kuros Biosciences Reports First Half of 2025 Results

Kuros Biosciences launches MagnetOs MIS Delivery System by completing first cases, and continues global expansion with incremental Brazil clearance

Kuros Biosciences to share latest MagnetOs™ market impact and strategic priorities at Capital Markets Day in Zürich

Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025

Annual General Meeting of Kuros Biosciences approves all resolutions

Kuros Biosciences grows sales to CHF 75.6 million for 2024

Kuros Biosciences USA, Inc. announces an exclusive strategic agreement with the Medtronic spinal division

Kuros Biosciences Expands into Extremities Markets

Kuros reports 149% increase in direct MagnetOs sales and exceeds cash flow breakeven in the first nine months of 2024

Kuros Biosciences Reports First Half of 2024 Results

Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft

Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales

Annual General Meeting of Kuros Biosciences approves all resolutions

Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023

Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update

Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference

Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand

Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA

Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA

Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages

Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management

Kuros Biosciences Reports Results for First Half 2023

Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial

Annual General Meeting of Kuros Biosciences approves all resolutions

Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023

Kuros Biosciences reports results for the full year 2022

Kuros Biosciences Announces Publication of Supportive Osteoimmunology Data for MagnetOs Bone Graft

Kuros Biosciences Announces Changes to Executive Management Team

Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH

Kuros Biosciences completes enrolment in Level 1 clinical study of MagnetOs Granules

Kuros reports 73% increase in MagnetOs sales in first nine months of 2022

Kuros Biosciences awarded 2022 Spine Technology Award for MagnetOs Flex Matrix by Orthopedics This Week

Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting

Kuros Biosciences Appoints Chris Fair as Chief Operating Officer

Kuros Biosciences announces successful CHF 6.0 million private placement

Kuros Biosciences’ MagnetOs Bone Graft Successfully Achieves Three Key Milestones

Kuros Biosciences reports results for the first six months of 2022

Annual General Meeting of Kuros Biosciences approves all resolutions

Kuros Biosciences: Completion of the acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals triggers a $5 million milestone payment

Kuros Biosciences announces favorable preliminary results of MagnetOs as standalone alternative to autograft in first randomized controlled trial

Kuros Biosciences announces commercial launch of MagnetOs Easypack Putty in the U.S.

Kuros Biosciences continues strong commercial roll-out of MagnetOs bone graft

Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences’s MagnetOs Flex Matrix Cleared by FDA for Spinal Indications

Kuros Biosciences reports results for the full year 2021

Kuros Biosciences reports continued increase in MagnetOs U.S. sales

Kuros Biosciences to showcase new MagnetOs products at NASS 2021 Annual Meeting

Kuros Biosciences Announces FDA 510(k) Clearance for MagnetOs Easypack Putty

Kuros Biosciences Reports Results for First Half 2021

Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuros’s license agreement with Checkmate Pharmaceuticals

Kuros Biosciences announces publication of data on MagnetOs in eCM Journal linking MOA to enhanced predictable bone regeneration

Kuros Biosciences to present at upcoming U.S. spine conferences

Kuros Biosciences’s commercial roll-out of MagnetOs bone graft exceeds expectations

Kuros to receive $4 million milestone payment from Checkmate Pharmaceuticals

Kuros Biosciences strengthens its patent position on use of Fibrin-PTH in spinal fusion

Annual General Meeting of Kuros Biosciences approves majority of resolutions

Kuros Biosciences treats first patient in clinical trial of MagnetOs Putty for posterolateral spine fusion

Kuros Biosciences announces treatment of first patient in Australia with MagnetOs for spine fusion

Kuros to receive $2 million milestone payment from Checkmate Pharmaceuticals

Kuros Biosciences publishes invitation to the Annual General Meeting 2021

Kuros Biosciences reports results for the full year 2020

Kuros Biosciences to present at upcoming clinical and investor conferences

Kuros Biosciences announces MagnetOs sales and distribution agreements across Northern Europe

Kuros Biosciences wins 2020 Spine Technology Award from Orthopedics This Week

Kuros announces final result of capital increase – total gross proceeds of CHF 18.6 million raised

Kuros announces results of Rights Offering

Kuros provides an update on the planned Capital Increase

Kuros Biosciences to present new data on the role of osteoimmunology in bone formation at NASS 2020 Annual Meeting

Kuros Biosciences reports MagnetOs products approved in Australia

Kuros announces all agenda items were approved at its Extraordinary General Meeting today and launches a discounted rights offering expected to raise up to CHF 15.2 million of gross proceeds

Kuros Biosciences Hosts an Expert Perspectives Webinar on Pioneering Solutions for Targeted and Controlled Bone Healing

Kuros reaches milestone of 2,000 patients treated with MagnetOs bone graft

Kuros Convenes Extraordinary General Meeting

Kuros Biosciences's licensee Checkmate Pharmaceuticals completes its IPO on NASDAQ

Kuros Biosciences Announces Treatment of the First Patient in its Spinal Fusion Trial with Fibrin-PTH

Kuros Biosciences Reports Results for First Half 2020

Kuros Biosciences further strengthens orthobiologics patent portfolio

Annual General Meeting of Kuros Biosciences approves all resolutions

Kuros Biosciences reports results for the full year 2019

Kuros strengthens orthobiologics patent portfolio

Kuros reports publication of MagnetOs preclinical data demonstrating superiority to market-leading synthetic bone grafts in spinal fusion

Kuros announces final result of Capital Increase – total gross proceeds of CHF 12.5 million raised

Kuros announces results of Rights Offering

Kuros provides an update on the Capital Increase

Kuros announces the terms of the proposed capital increase through a discounted rights offering expected to raise up to CHF 12 million gross proceeds for the commercialization of its products and the further development of its product candidates

Extraordinary General Meeting of Kuros Biosciences approves all resolutions

Kuros convenes Extraordinary General Meeting

Kuros Biosciences to Host Key Opinion Leader Meeting in Zurich Showcasing its Commercial Stage Advanced Bone Graft MagnetOs

Kuros Biosciences announces full commercial launch of MagnetOs™ and exhibitor status at North American Spine Society 34 th Annual Meeting

Kuros Biosciences Announces U.S. FDA approval of IND Application to Initiate Fibrin-PTH Phase 2a Clinical Trial in Spinal Fusion

Kuros Biosciences Reports Results for First Half 2019

Kuros announces Gerhard Ries is stepping down as Board member

Extraordinary General Meeting of Kuros Biosciences approves all resolutions

Kuros Biosciences signs agreement with Surgical Specialties on distribution of MagnetOs in Australia and New Zealand

Kuros Biosciences to propose adjustment of authorized and conditional capital at extraordinary general meeting to retain a flexible capital structure

Annual General Meeting of Kuros Biosciences approves certain resolutions

Kuros Biosciences to propose re-appointment of Chairman and Board Members at Annual General Meeting

Kuros Biosciences reports results for the full year 2018

Kuros Biosciences enters convertible bond financing agreement for up to CHF 5 million

Kuros Biosciences receives US marketing clearance for intervertebral body fusion device

Kuros Biosciences signs agreement to supply SeaSpine with bone graft incorporating Kuros's advanced submicron surface technology

Kuros ends transformational year with first MagnetOs sales, lead clinical program on track, and successful capital raise

Kuros announces final result of capital increase – total gross proceeds of 16.1 million raised

Kuros announces results of rights offering – capital increase will be implemented

Kuros receives FDA 510(k) clearance for extending commercial indications of MagnetOs Putty in the United States

Kuros reports publication of MagnetOs data demonstrating equivalence to autologous bone in spinal fusion

Extraordinary General Meeting of Kuros Biosciences approves all resolutions

Kuros announces the final terms of the proposed capital increase through a discounted rights offering expected to raise up to CHF 20 million gross proceeds to advance its pipeline

Kuros convenes Extraordinary General Meeting

Kuros Biosciences obtains US patent covering a method for producing osteoinductive materials

Kuros Biosciences advances its Fibrin-PTH (KUR-113) spinal fusion product candidate program

Kuros reports first patient treated in randomized controlled trial of MagnetOs in spinal fusion

Kuros Biosciences appoints Strategic Advisory Board

Kuros Biosciences to Host Key Opinion Leader Meeting on Establishing the New Gold Standard in Bone Regeneration

Kuros Biosciences Reports Results for First Half 2018

Kuros Biosciences appoints Pascal Longlade as Chief Medical Officer

Kuros Biosciences reports first U.S. & UK sales of MagnetOs Commercial roll-out in the U.S. and Europe on track

Kuros Biosciences to present promising clinical case studies with MagnetOs at leading spine surgery conference

General Meeting of Kuros Biosciences approves all resolutions

Kuros Biosciences announces start of of randomized controlled trial of MagnetOs in spinal fusion Study should further enhance competitive positioning of MagnetOs

Kuros Biosciences to propose appointment of new Board Members at AGM

Kuros announces start of investigator-led study of MagnetOs Granules for maxillary sinus floor elevation

Kuros Biosciences receives European clearance for MagnetOs Putty and prepares for commercial roll-out in the U.S. and Europe

Kuros Biosciences Reports Full-Year 2017 Results

Kuros Biosciences obtains European patent covering osteoinductive materials

Kuros Biosciences Expands License Agreement with Checkmate

Kuros Biosciences Announces Management Succession

Kuros Biosciences' Chief Medical Officer to Retire

Kuros Biosciences May Secure Equity Financing of up to CHF 30 million

Kuros announces management changes

Kuros Biosciences Reports Financial Results for First Half-Year of 2017

Kuros receives clearance for MagnetOs Putty for commercialization in the United States and files the product for CE marking in Europe

Kuros Biosciences announces full exercise of over-allotment option

Kuros Biosciences strengthens equity base with placement of new shares

Kuros receives CE certification for Neuroseal ®, a novel dural sealant

Kuros Biosciences launches rights and share offering

Kuros Biosciences submits MagnetOs Putty for US FDA Clearance

General Meeting of Kuros Biosciences approves all resolutions

Kuros prepares for commercialization of its lead products and considers share placement

Kuros Biosciences Proposes Election of Four New Board Members

Kuros Biosciences Reports Financial Results for 2016

Kuros announces CEO succession

Kuros closes acquisition of Xpand creating a leading commercial-stage orthobiologics company

Kuros submits regulatory filing seeking CE certification for Neuroseal, a novel dural sealant

Kuros to acquire Xpand in an all-share strategic transaction to create a leading commercial stage orthobiologics company

Kuros Biosciences' KUR-112 Receives Rare Pediatric Disease Designation

Kuros Biosciences Reports Financial Results for First Half-Year of 2016

Arbutus terminates license agreement for VLP platform for the treatment of hepatitis B infections

Kuros appoints Philippe Saudan as Chief Development Officer

valuationLAB Initiates Research Coverage on Kuros

First Trading Day of New Kuros Share after Reverse Split

Kuros Bioscience's Shareholders Approve All Resolutions

Kuros Invites to the Annual Shareholders' Meeting 2016

Kuros Biosciences Reports Financial Results for 2015

Kuros receives milestone payment from Checkmate

Kuros Biosciences Ltd. appoints Chief Medical Officer

Kuros Biosurgery Holding Ltd. closes merger with Cytos Biotechnology Ltd. which is renamed Kuros Biosciences Ltd.

Cytos Biotechnology Ltd. will be renamed Kuros Biosciences Ltd., constitutes its Board of Directors and appoints Executive Officers

Extraordinary Shareholders' Meeting of Cytos Biotechnology Ltd. approves all resolutions